Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 601–700 of 963
Bakhashab, S., O’Neill, J., Barber, R., Arden, C., & Weaver, J. U. (2024) · Biomedicines · doi:10.3390/biomedicines12010171 · Cited by 6
“The risk of CVD mortality is still increased by almost three times in those with T1DM even when it is well-controlled with stable glycemic levels [4].”
BackgroundAzad, A., Altunbaş, H., & Manguoğlu, A. E. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347263 · Cited by 5
Šuran, D., Kanič, V., Naji, F. H., Krajnc, I., Čokolič, M., Zemljič, E., & Sinkovič, A. (2019) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2019.4250 · Cited by 6
Turton, J. L., Struik, N. A., Riley, M. D., & Brinkworth, G. D. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.09.009 · Cited by 5
Epidemiology of Type 1 Diabetes
Stene, L. C., & Tuomilehto, J. O. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch4 · Cited by 10
Fragozo-Ramos, M. C., Schenker, G., Hepprich, M., Gallo‐Villegas, J., Züger, T., & Garcia‐Tirado, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335060 · Cited by 6
Isaksson, S. S., Hellman, J., Wijkman, M., Imberg, H., Ólafsdóttir, A. F., Axelsen, M., & Lind, M. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101619 · Cited by 6
Self-citationFrom survival to freedom: redefining success in type 1 diabetes
Piemonti, L. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00003-3 · Cited by 4
Social and Structural Determinants of Cardiovascular Complications of Diabetes
MENSAH, P. A., VALDEZ, K., Gyawali, A., & Snell‐Bergeon, J. K. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01541-7 · Cited by 5
Trends in Survival After First Myocardial Infarction in People With Diabetes
Glynn, L., Lind, M., Andersson, T., Eliasson, B., Hofmann, R., & Nyström, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034741 · Cited by 5
Self-citationCamoin, M., Mohammedi, K., Saulnier, P., Hadjadj, S., Gautier, J., Riveline, J., Venteclef, N., Potier, L., & Velho, G. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae852 · Cited by 3
Regulatory T cell-based therapies for type 1 diabetes: a narrative review
Velikova, T. V., Vasilev, G., Linkwinstar, D., Siliogka, E., Kokudeva, M., Miteva, D., Vasilev, G., Gulinac, M., Atliev, K., & Shumnalieva, R. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.52 · Cited by 5
Paliares, I. C., Dualib, P. M., Aroucha, P. M. T., Torres, L. S. N., de Sá, J. R., & Dib, S. A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112386 · Cited by 6
Grönberg, A., & Swenne, I. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000209 · Cited by 4
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2020) · PubMed Central · Cited by 5
SNAITH, J. R., & Greenfield, J. R. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51637 · Cited by 5
Isaksson, S. S., Ólafsdóttir, A. F., & Lind, M. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1114317 · Cited by 4
“Mortality remains considerably higher in patients with T1D which could be decreased significantly if more patients reached target blood glucose levels (3, 4).”
BackgroundSelf-citationMinasian, V., & Nazari, M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122114 · Cited by 7
Rollborn, N., Larsson, A. O., & Kultima, K. (2024) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2024.2303720 · Cited by 4
Murillo, S., Brugnara, L., Ríos, S., Ribas, V., Servitja, J., & Novials, A. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111655 · Cited by 6
Farthing, P., Bally, J. M. G., & Rennie, D. (2024) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2024.04.002 · Cited by 4
Janić, M., Janež, A., Šabović, M., El‐Tanani, M., Rangraze, I. R., Rizzo, M., & Lunder, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226860 · Cited by 8
Risk Factors for Developing Advanced Chronic Kidney Disease in Pancreas Transplant Alone Recipients
Parajuli, S., Zona, E. E., Breyer, I. C., Tamburrini, R., Astor, B. C., Radke, N., Mandelbrot, D. A., Kaufman, D. B., & Odorico, J. S. (2024) · Transplantation · doi:10.1097/tp.0000000000005273 · Cited by 4
Mesa, A., Puig-Jové, C., Pané, A., Vinagre, I., López‐Quesada, E., Meler, E., Alonso-Carril, N., Quirós, C., Amor, A. J., & Perea, V. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02719-3 · Cited by 4
Nilsson, J., Åkesson, K., Hanberger, L., & Samuelsson, U. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12498 · Cited by 6
Artificial intelligence-based decision support systems for diabetes
Contreras, I., Bertachi, A. H., Biagi, L., Oviedo, S., Ramkissoon, C. M., & Vehí, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817133-2.00014-8 · Cited by 4
Abdominal Organ Transplantation: Noteworthy Literature in 2020
Wang, R. F., Fagelman, E., Smith, N. K., & Sakai, T. (2021) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/10892532211007256 · Cited by 4
Gao, Y., Chen, S., Gu, W., Fang, C., Huang, Y.-T., Gao, Y., Lu, Y., Su, J., Wu, M., Zhang, J., et al. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2073 · Cited by 4
Automated Adaptation of Insulin Treatment in Type 1 Diabetes
Fabris, C., Gautier, T., & Breton, M. D. (2021) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc46164.2021.9630191 · Cited by 7
JENDLE, J. H., Agvall, B., Galozy, A., & Adolfsson, P. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221096423 · Cited by 6
Glutamic acid decarboxylase immunotherapy for type 1 diabetes
Ludvigsson, J. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000748 · Cited by 4
Characteristics and outcomes of patients with type 1 diabetes admitted with acute coronary syndromes
Nejatian, M. M., Lan, N. S. R., Yeap, B. B., Dwivedi, G., Fegan, P. G., & Ihdayhid, A. R. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110093 · Cited by 4
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
Sokolov, V., Yakovleva, T. A., Stolbov, L. A., Penland, R. C., Boulton, D. W., PARKINSON, J. R., & Tang, W. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12956 · Cited by 4
Courtney, A., Smith, D., & Forde, H. E. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03322-9 · Cited by 4
Metabolic and endocrine evaluation of islet transplant function
Rickels, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00045-9 · Cited by 6
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00769-1 · Cited by 5
Quirós, C., Viñals, C., Giménez, M., Roca, D., & Conget, I. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2019.03.013 · Cited by 7
Lin, C., Chang, C., & Chuang, L. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13420 · Cited by 3
“During the 5-year follow-up period, baseline A1C and mean A1C were significantly associated with both fatal/non-fatal coronary heart disease and fatal/non-fatal CVD. Lind et al.11 followed 33,915 type 1 diabetes patients over a period of 8 years, and found a trend of increasing all-cause and cardiovascular mortality w…”
BackgroundPopovic, D. S., Koufakis, T., & Παπάνας, Ν. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230817105105 · Cited by 4
Martino, N. D., Angelino, S., Maio, A., Cirillo, P., Pontillo, A., Caputo, M., Scappaticcio, L., Caruso, P., Longo, M., Bellastella, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189196 · Cited by 3
“Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals with T1D, remaining 4.2 times higher in people with T1DM compared with non-diabetic controls [6,12–14].”
InfluentialCichosz, S. L., Thomsen, C. H. N., Klonoff, D. C., Hirsch, I. B., & Jensen, M. H. (2026) · PLOS Digital Health · doi:10.1371/journal.pdig.0001229 · Cited by 4
“Large population-based studies evaluating patient prognosis over extended periods have traditionally relied on HbA1c measurements [2,3].”
Mertens, J., Stoop, T., Dirinck, E. L., Francque, S., Heuten, H., & Block, C. E. M. D. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03114-2 · Cited by 4
Larsson, A. O., Vallée, M., Havelka, A. M., Larsson, A. O., Elmgren, A., Larsson, B., Sisowath, C., Nordin, G., Hansson, L., Lohmander, M., et al. (2019) · Journal of Diabetes Metabolism and its Complications · doi:10.31487/j.jdmc.2019.01.03 · Cited by 4
“SNDR strives to improve the quality of care of Swedish diabetes patients by providing tools for monitoring the performance of the care and HbA1c is one of the most important biomarkers used for this monitoring [2, 5].”
BackgroundMethodHohendorff, J., Kwiatkowska, M., Pisarczyk-Wiza, D., Ludwig‐Słomczyńska, A. H., Milcarek, M., Kapusta, P., Zapała, B., Kieć‐Wilk, B., Trznadel-Morawska, I., Szopa, M., et al. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16143 · Cited by 3
More hypoglycemia not associated with increasing estimated adiposity in youth with type 1 diabetes
Sarteau, A. C., Kahkoska, A. R., Crandell, J., IGUDESMAN, D. A., Corbin, K. D., Kichler, J., Maahs, D. M., Muntis, F. R., Pratley, R. E., Seid, M., et al. (2022) · Pediatric Research · doi:10.1038/s41390-022-02129-1 · Cited by 5
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 4
Fayyaz, F., Khosravi, S., Mosallanejad, A., Tabatabaei‐Malazy, O., Nazari, S. S. H., & Shaghaghi, M. (2023) · Intern J Endocrinol Metab · doi:10.5812/ijem-138377 · Cited by 4
Glycaemic control following total pancreatectomy: room for improvement?
Shapey, I. M., Alfred, J., Sharp, R., Whelan, P., Szatmary, P., Mann, K., Dunne, D., Raraty, M. G. T., Ghaneh, P., Halloran, C. M., et al. (2024) · HPB · doi:10.1016/j.hpb.2024.04.015 · Cited by 3
Beta-adrenergic agonism protects mitochondrial metabolism in the pancreatectomised rat heart
Lindsay, R. T., Thisted, L., Zois, N. E., Thrane, S. T., West, J. A., Fosgerau, K., Griffin, J. L., Fink, L. N., & Murray, A. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-70335-4 · Cited by 3
Casas, R., Tompa, A., Åkesson, K., Teixeira, P. F., Lindqvist, A., & Ludvigsson, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010374 · Cited by 6
He, B., Liu, Z.-Z., Xu, R.-Y., Li, F., Guo, R., Deng, C., Xie, Y., Zhou, Z., & Li, X. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104024 · Cited by 6
Diabetische Nephropathie: Aktuelle Diagnostik und Therapie
Werth, S. C., Lehnert, H., & Steinhoff, J. (2015) · Der Internist · doi:10.1007/s00108-014-3629-0 · Cited by 5
Adjunct Therapies In Type 1 Diabetes
Dandona, P., Kuhadiya, N. D., Ghanim, H., & Chaudhuri, A. (2016) · Endocrine Practice · doi:10.4158/ep151113.co · Cited by 3
Co-Managing Patients with Type 1 Diabetes and Cancer
Best, C. J., Thosani, S., Ortiz, M. R., Levesque, C. A., Varghese, S. S., & Lavis, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0766-y · Cited by 5
Aeppli, T. R. J., Mahler, F. L., & Konrad, D. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0152 · Cited by 4
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials
Min, T., & Bain, S. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2188191 · Cited by 4
Forner, P. M., SNAITH, J. R., & Greenfield, J. R. (2023) · Internal Medicine Journal · doi:10.1111/imj.16312 · Cited by 6
Karipidou, M., Liatis, S., Kyrkili, A., Skoufi, A., Lambadiari, V., Tigas, S. K., Liberopoulos, E. N., & Kontogianni, M. D. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103868 · Cited by 4
Type 1 Diabetes Mellitus and Dyslipidemia
Maahs, D. M., & Eckel, R. H. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_7 · Cited by 4
Insulin sensitizer prevents and ameliorates experimental type 1 diabetes
Valitsky, M., Hoffman, A., Unterman, T. G., & Bar‐Tana, J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2016 · Cited by 4
Letunica, N., Cai, T., Cameron, F. J., Monagle, P., Ignjatović, V., & Attard, C. (2021) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202000060 · Cited by 3
Neue Technologien in der Diabetologie: Wie weit ist es noch bis zum Closed-loop-System?
Freckmann, G. (2015) · Der Internist · doi:10.1007/s00108-014-3627-2 · Cited by 3
The evolving frontier of diabetes therapy: The renaissance of glycemology
Ceriello, A., Genovese, S., & Bosi, E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.036 · Cited by 3
Walz, L., Jönsson, A. K., Zilg, B., Östgren, C. J., & Druid, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164950 · Cited by 3
Tendencias de la mortalidad por diabetes en España: por el buen camino
Cabezas-Agrícola, J. M. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.12.019 · Cited by 6
Somily, A. M., & Babay, H. A. H. (2008) · Europe PMC (PubMed Central) · Cited by 4
Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
Translational Research Symposium—collaborative efforts as driving forces of healthcare innovation
Coentro, J. Q., Pieri, A. D., Gaspar, D., Tsiapalis, D., Zeugolis, D. I., & Bayon, Y. (2019) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-019-6339-2 · Cited by 3
“There is a clear need for patient-friendly treatment and, ideally, a cure [28].”
BackgroundDiagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Holder, M., Kapellen, T. M., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R. W., Holterhus, P., Karges, B., Kordonouri, O., et al. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3388 · Cited by 6
New technical approach to the diabetes therapy
Dovč, K., & Battelino, T. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05865-x · Cited by 3
Trends in Mortality From Diabetes in Spain: On the Right Way
Cabezas-Agrícola, J. M. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.031 · Cited by 4
Marfella, R., Onofrio, N. D., Scisciola, L., Maiello, C., Trotta, M. C., Sardu, C., Capuano, A., Barbieri, M., Balestrieri, M. L., Claudio Napoli, A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4135653 · Cited by 3
Ceriello, A., & Prattichizzo, F. (2022) · Diabetes Care · doi:10.2337/dc22-1641 · Cited by 3
Also the parents of children with type 1 diabetes need psychological support
Ludvigsson, J. (2024) · Acta Paediatrica · doi:10.1111/apa.17188 · Cited by 4
Zabala, A., Gottsäter, A., Lind, M., Eliasson, B., Bertilsson, R., Ekelund, J., Jonsson, M., & Nyström, T. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231176767 · Cited by 3
Self-citationFayyaz, F., Mardi, P., Sobhani, S., Sokoty, L., Aghamahdi, F., & Qorbani, M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01351-w · Cited by 5
Gregory, J. M., Smith, T. J., Duffus, S. H., Brooks, D., Akbar, M. N., Huntley, M., Gottlieb, J., LeStourgeon, L. M., Wilson, C., Beckman, J. A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02658-z · Cited by 2
Excess mortality in type 1 diabetes patients in Belgium: A population based study
de Meester, C., Ginckel, A. V., Vinck, I., Eyssen, M., & Castanares‐Zapatero, D. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112426 · Cited by 2
Mantovani, M., Kwiendacz, H., Irlik, K., Bucci, T., Hendel, M., Lam, S. H. M., Huang, B., Szromek‐Białek, P., Niezgoda, M., Alam, U., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70136 · Cited by 3
Thomas, J. J. C., Lanzinger, S., Soerensen, K., Imberg, H., Schmid, S., Barron, E., Holl, R. W., Pedersen‐Bjergaard, U., Adler, A., Vettoretti, M., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70112 · Cited by 5
Self-citationMathiesen, D. S., Hansen, J. V., Høck, A., Nielsen, C. K., Pedersen, M. G., Kristensen, P. L., Andersen, H. U., Aarestrup, M. L., Forman, J. L., Bagger, J. I., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70139 · Cited by 2
Basset‐Sagarminaga, J., Block, C. E. M. D., Nørgaard, K., O'Neal, D. N., van den Heuvel, T. R. A., Taplin, J., Smaniotto, V., & Cohen, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70211 · Cited by 2
Lan, N. S. R., Ryan, C. D., Rudén, A., Glasby, J. R. K., Nanayakkara, N., Elghattis, Y., Brazionis, L., Huang, M., Lum, S., Januszewski, A. S., et al. (2025) · Internal Medicine Journal · doi:10.1111/imj.70276 · Cited by 3
Seaton, K. M., Jones, H. C., Lee, M. H., Kilov, G., Jenkins, A. J., Wu, L. M., Pham, C. T., Gao, F. M., Ekinci, E. I., Taylor, P., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113136 · Cited by 2
Simon-Guth, S., Hedberg, E., & Roxhed, N. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2635921 · Cited by 3
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.11.004 · Cited by 7
“po parece ser el factor más relevante, mientras que otros FR: PA y colesterol de las lipoproteínas de baja densidad (cLDL) cobran importancia 15-20 años después del diagnóstico (36-38).”
Goryunov, S. V., Prividentsev, A. I., Manturova, N. E., & Stupin, V. A. (2021) · Plastic Surgery and Aesthetic Medicine · doi:10.17116/plast.hirurgia202102148 · Cited by 2
The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies
Ma, J., Zhao, Y., Fan, H., & Liu, J. (2021) · African Health Sciences · doi:10.4314/ahs.v21i1.2 · Cited by 3
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease
Karalliedde, J. J., Winocour, P. H., Chowdhury, T. A., De, P., Frankel, A., Montero, R., Pokrajac, A., Banerjee, D., Dasgupta, I., Fogarty, D. G., et al. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2021.328 · Cited by 2
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01048-x · Cited by 2
Jin, Q., Zhao, T., Lin, L., Yao, X., Teng, Y., Zhang, D., Jin, Y., & Yang, M. (2023) · Human Cell · doi:10.1007/s13577-023-00952-0 · Cited by 2
Poon, M., Chan, A. K. F., Cusumano, J. M., Craig, M. E., & Donaghue, K. C. (2024) · Pediatric Diabetes · doi:10.1155/2024/8194756 · Cited by 2
Ferraz, L. C., Barros, M., Almeida, K. M. M., Galdino-Silva, M. B., & Bueno, N. B. (2024) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2024e13649 · Cited by 2
Rangel, M. A., Calejo, R., Lopes, V., Campos, R. A., & Leite, A. L. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.09.004 · Cited by 2
Simeunovic, A., Brunborg, C., Heier, M., Berg, T. J., Dahl‐Jørgensen, K., & Margeirsdottir, H. D. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004505 · Cited by 2
Rabbone, I., Savastio, S., Castorani, V., Chiarle, E., Ferrari, A., Pozzi, E., Cavalli, C., & Scaramuzza, A. E. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0057 · Cited by 7
Dilek, S. O., & Çömlek, F. Ö. (2025) · Children · doi:10.3390/children12040463 · Cited by 3
“In children and adolescents with T1D, tight metabolic control with insulin therapy is associated with low hemoglobin A1c (HbA1c) levels and reduced macrovascular and microvascular complications [6].”
Unawereness of low physical activity in people with type 1 diabetes
Sundberg, F. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.07.005 · Cited by 3
Diabetes and Coronary Artery Disease – Pathophysiologic Insights and Therapeutic Implications
Fridman, D., Makaryus, A. N., Makaryus, J. N., Bhanvadia, A., Qaja, E., Masters, A., & McFarlane, S. I. (2015) · InTech eBooks · doi:10.5772/61875 · Cited by 3
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.